id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-E-5040-0006,FDA,FDA-2017-E-5040,"Determination of Regulatory Review Period for Purposes of Patent
Extension; ADLYXIN",Notice,Determinations,2018-12-26T05:00:00Z,2018,12,2018-12-26T05:00:00Z,2019-02-26T04:59:59Z,2019-01-10T02:33:03Z,2018-27805,0,0,09000064839c4db3
FDA-2017-E-5040-0005,FDA,FDA-2017-E-5040,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2018-12-21T05:00:00Z,2018,12,2018-12-21T05:00:00Z,,2018-12-21T18:20:50Z,,0,0,09000064839c0827
FDA-2017-E-5040-0004,FDA,FDA-2017-E-5040,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2018-10-01T04:00:00Z,2018,10,2018-10-01T04:00:00Z,,2018-10-01T18:48:38Z,,0,0,0900006483788b0e